Scantox Group
Biotechnology ResearchZealand, Denmark51-200 Employees
Scantox Group is a preclinical CRO focused on drug development and regulatory toxicology, offering services across discovery, genetic toxicology, regulatory toxicology, and pharmaceutical development and analytical work. The company supports pharmaceutical and medical devices clients by generating robust data to advance their nonclinical programs to high technical and scientific standards, grounded in decades of experience. Based in Ejby, Denmark, with a network of subsidiaries in the UK, Austria, Denmark and Sweden, Scantox operates within the biotechnology research sector and is positioned as a trusted partner for nonclinical development needs. Founded in 1977, the group emphasizes a purpose-driven approach and has pursued growth through acquisitions and service expansion, including recent developments such as the launch of new mutagenesis and blood-brain barrier disruption capabilities. The organization is headquartered in Denmark and serves clients seeking comprehensive nonclinical testing and safety assessments for pharmaceuticals and devices.